阿得贝利单抗(Adebrelimab) - 药物靶点：PDL1_在研适应症：广泛期小细胞肺癌，晚期肝细胞癌，局限期小细胞肺癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

HTI-1088、HTI-1316、SHR 1316

+ [2]

靶点

PDL1

作用方式

抑制剂

作用机制

PDL1抑制剂(程序性死亡配体1抑制剂)

治疗领域

肿瘤呼吸系统疾病消化系统疾病+ [4]

在研适应症

广泛期小细胞肺癌晚期肝细胞癌局限期小细胞肺癌+ [45]

非在研适应症

晚期食管鳞状细胞癌HR阳性/HER2低表达实体瘤复发性小细胞肺癌

原研机构

在研机构

+ [3]

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

中国 (2023-02-28),

广泛期小细胞肺癌

最高研发阶段(中国)批准上市

特殊审评特殊审批 (中国)

登录后查看时间轴

结构/序列

Sequence Code 13388064H

来源: *****

Sequence Code 13388069L

来源: *****

关联

272

项与阿得贝利单抗相关的临床试验

NCT07069270

/ Not yet recruiting临床2期IIT

A Prospective, Single-center, Single-arm Clinical Study of Adebrelimab in Combination With Vunakizumab and Chemotherapy as First-line Treatment for Extensious-stage Small Cell Lung Cancer

This study is a prospective, single-center, single-arm clinical trial, with a planned enrollment of 28 cases.The first Adebrelimab +Vunakizumab +EC was administered within 72 hours after enrollment for 4 to 6 cycles.At the end of the combination phase, non-PD subjects entered the maintenance treatment period of Adebrelimab plus Vunakizumab.Treatment will continue until any of the following situations occur: disease progression in the subject, intolerable toxic and side effects, comorbidiments that affect further treatment, the investigator's decision to withdraw the subject from the study, or other reasons for non-compliance with the study treatment or the study procedures or protocols.

开始日期2025-09-01

申办/合作机构

福建省肿瘤医院（福建省肿瘤研究所、福建省癌症防治中心）

NCT07110571

/ Not yet recruiting临床2期

A Multi-cohort, Multi-center Phase II Clinical Study of Adebrelimab in Combination With SHR-A1811/SHR-A1904 and Chemotherapy or Adebrelimab in Combination With SHR-8068 as the Treatment in Subjects With Gastric or Gastroesophageal Junction Cancer

This is a multi-cohort, multi-center Phase II clinical study exploring the efficacy of treatment with either Adebrelimab plus SHR-A1811/SHR-A1904 and chemotherapy, or Adebrelimab plus SHR-8068 in patients with gastric or gastroesophageal junction (GEJ) cancer. The study also evaluates the safety and tolerability of these combination regimens.

开始日期2025-08-01

申办/合作机构

苏州盛迪亚生物医药有限公司

NCT07063407

/ Not yet recruiting临床1期

A Phase I Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer

This is a Phase I clinical study of HS-20093. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).

开始日期2025-07-31

申办/合作机构

上海翰森生物医药科技有限公司

100 项与阿得贝利单抗相关的临床结果

登录后查看更多信息

100 项与阿得贝利单抗相关的转化医学

登录后查看更多信息

100 项与阿得贝利单抗相关的专利（医药）

登录后查看更多信息

38

项与阿得贝利单抗相关的文献（医药）

2025-07-01·BMJ Open Gastroenterology

Adebrelimab plus capecitabine versus capecitabine monotherapy for adjuvant treatment of high-risk resected cholangiocarcinoma (ACHIEVE): protocol for a phase II, multicentre, randomised controlled trial

Article

作者: Cheng, Yuan ; Li, Xiangcheng ; Li, Changxian ; Zhang, Yaodong

Introduction:

Cholangiocarcinoma (CCA) carries a high risk of recurrence even after curative resection. Capecitabine is standard adjuvant therapy, but recurrence rates remain significant, particularly in high-risk patients. Immunotherapy has shown promise in advanced CCA, prompting investigation into its role in earlier settings.

Methods and analysis:

This multicentre, randomised, open-label phase II trial will compare adjuvant adebrelimab plus capecitabine versus capecitabine alone in patients with high-risk resected CCA. The study is being conducted at four tertiary hospitals in Jiangsu Province, China. Eligible patients will be randomised 1:1. The primary endpoint is 1-year recurrence-free survival rate (1y-RFS rate). Secondary endpoints are overall survival, RFS and safety. Exploratory endpoints are circulating tumour DNA (ctDNA)-based MRD assessment.

Ethics and dissemination:

The study is approved by the Institutional Review Board of Jiangsu Provincial People’s Hospital (2024-SR571). Informed consent will be obtained from all participants. The findings will be published in peer-reviewed journals and presented at scientific conferences.

Trial registration number:

NCT06607276.

2025-06-01·BMJ Open

Clinical study of adebrelimab in combination with apatinib and irinotecan for PD-1 inhibitor-ineffective advanced-stage gastric cancer: study protocol for a single-arm, single-centre, exploratory trial

Article

作者: Xia, Xiang ; Guan, Yujing ; Bai, Long ; Aimaiti, Muerzhate ; Zhang, Hao-yu ; Wang, Shuchang ; Ni, Bo ; Yue, Ben ; Gu, Jiayi ; Liu, Tao ; Zhang, Zizhen ; Zhang, Yeqian

Introduction:

Immunotherapy has revolutionised cancer treatment. Immune checkpoint inhibitors have demonstrated significant efficacy across multiple tumour types, including gastric cancer, where several approved programmed cell death 1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitors show promising antitumour activity. While PD-L1 expression serves as a predictive biomarker for PD-1 inhibitor response, and PD-L1-positive patients generally show better outcomes, therapeutic resistance remains a challenge. Many initial responders eventually develop resistance, and surprisingly, some PD-L1-positive patients fail to achieve expected response rates, indicating emerging resistance mechanisms in potentially responsive populations. Adebrelimab, a PD-L1 inhibitor, demonstrates mechanistic advantages over PD-1 inhibitors, with clinical studies suggesting promising therapeutic potential. When combined with irinotecan, apatinib has shown efficacy in second-line gastric cancer treatment. This study aims to evaluate the efficacy and safety of combining adebrelimab with apatinib and irinotecan for advanced gastric cancer refractory to PD-1 inhibitors.

Method and analysis:

This single-arm, single-centre exploratory trial will be conducted at Renji Hospital, enrolling 32 patients aged 18–75 years. Eligible patients must have initially achieved partial response, complete response or stable disease with progression-free survival (PFS)≥3 months during prior immunotherapy but subsequently progressive disease on imaging. Treatment will continue until meeting discontinuation criteria. The primary endpoint is objective response rate with Clopper-Pearson 95% CI. Secondary endpoints include disease control rate (95% CI), PFS and overall survival (estimated by Kaplan-Meier method), along with safety assessments.

Ethics and dissemination:

All participants will provide informed consent. The protocol has been approved by the Shanghai Jiaotong University School of Medicine, Renji Hospital Ethics Committee (LY2023-201-C). The results will be disseminated through peer-reviewed manuscripts, reports and presentations.

Trial registration number:

ChiCTR2300077329.

2025-05-01·Clinical Lung Cancer

Phase I Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation-Supported Dose-Intensified Chemotherapy With Adebrelimab as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Article

作者: Zhang, Jiexia ; Zhou, Chengzhi ; Xie, Zhanhong ; Liu, Ming ; Lin, Xinqing ; Qin, Yinyin ; Guan, Wenhui ; Xu, Xin ; Li, Zekun ; Huang, Zhenqian ; Xie, Xiaohong ; Qiu, Guihuan

BACKGROUND:

Small cell lung cancer (SCLC) is initially highly sensitive to chemotherapy, which often leads to significant tumor reduction. However, the majority of patients eventually develop resistance, and the disease is further complicated by its "cold" tumor microenvironment, characterized by low tumor immunogenicity and limited CD8+ T cell infiltration. These factors contribute to the poor response to immunotherapy in many cases of extensive-stage SCLC (ES-SCLC). High-dose chemotherapy has shown potential in enhancing tumor cytoreduction, but its use is often limited by severe hematologic toxicity. Combining chemotherapy with immune checkpoint inhibitors (ICIs) can create a synergistic effect by promoting immunogenic cell death and enhancing immune activation. Autologous hematopoietic stem cell transplantation (auto-HSCT) provides a means to support hematopoietic recovery, mitigate chemotherapy-induced myelosuppression, and contribute to immune reconstitution. In this context, the integration of auto-HSCT with dose-intensified chemotherapy and ICIs aims to both protect the bone marrow and enhance antitumor immune responses, potentially overcoming resistance to immunotherapy in ES-SCLC.

METHODS:

A phase I, single-center, single-arm trial was designed to evaluate the safety and efficacy of auto-HSCT-supported dose-intensified chemotherapy combined with adebrelimab in treatment-naive ES-SCLC patients. Participants will receive induction chemotherapy followed by stem cell mobilization, apheresis, and cryopreservation. After successful mobilization, consolidation chemotherapy with stem cell reinfusion and granulocyte colony-stimulating factor (G-CSF) support will be performed. Maintenance therapy with adebrelimab continues until disease progression or unacceptable toxicity. Safety and efficacy data, including adverse events, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS), will be analyzed.

RESULTS:

The study aims to enhance treatment outcomes by overcoming resistance to immuno-chemotherapy and promoting immune reconstitution. The trial is ongoing at the First Affiliated Hospital of Guangzhou Medical University.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT06597513.

336

项与阿得贝利单抗相关的新闻（医药）

21 小时之前

·医药经济报

AZ哮喘药在华再添新适应症，恒瑞、迪哲新药在美获新突破

阿斯利康哮喘新药获批新适应症 8月7日，阿斯利康宣布，其中国首个呼吸生物制剂本瑞利珠单抗注射液（商品名：凡舒卓）新适应症在中国正式批准，用于儿童（6至＜12岁）重度嗜酸粒细胞性哮喘（SEA）的维持治疗。本瑞利珠单抗是精准靶向嗜酸性粒细胞的抗IL-5R生物制剂，此前已在中国获批用于成人和12岁及以上青少年SEA的维持治疗。此次批准是基于全球多中心、开放标签的TATE Ⅲ期临床试验的积极结果。在该临床试验中，本瑞利珠单抗达到了主要研究终点，显示其在6-11岁SEA儿童中，具有良好的药代动力、药效特征与安全性，与青少年及成人研究结果一致，支持其在儿童群体中使用。本瑞利珠单抗采用皮下注射方式，前三次每4周注射一次，之后每8周注射一次。恒瑞医药ADC在美获孤儿药资格认定 8月6日，恒瑞医药发布公告称，其HER2 ADC注射用瑞康曲妥珠单抗联合阿得贝利单抗注射液和化疗用于胃癌或胃食管结合部腺癌适应症获得FDA授予的孤儿药资格认定。本次瑞康曲妥珠单抗获得FDA孤儿药资格认定，将有机会在产品研发、注册及商业化等方面获得美国的政策支持。瑞康曲妥珠单抗可通过与HER2表达的肿瘤细胞结合并内吞，在肿瘤细胞溶酶体内通过蛋白酶剪切释放毒素，诱导细胞周期阻滞,，使肿瘤细胞凋亡。其释放的毒素具有高透膜性，可发挥旁观者杀伤效应，进一步提高抗肿瘤疗效。瑞康曲妥珠单抗已于2025年5月在国内获批上市，适用于治疗存在HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者，是国内首个获批用于HER2突变NSCLC患者的国产ADC。迪哲医药新药在美获快速通道认定 8月6日，迪哲医药发布公告称，其在研产品DZD8586获FDA授予快速通道认定，用于既往接受过至少两线治疗（包括BTK抑制剂和BCL-2抑制剂）的复发难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）。 DZD8586是迪哲医药自主研发的全球首创LYN/BTK双靶点抑制剂，可同时阻断BTK依赖性和非依赖性BCR信号通路，抑制降解剂的耐药突变，对TEC家族其他成员具有高选择性，且可完全穿透血脑屏障。此次被FDA授予“快速通道认定”，是基于DZD8586针对既往接受过共价或非共价BTK抑制剂及BTK降解剂治疗的CLL/SLL患者的Ⅰ/Ⅱ期临床研究汇总分析。研究数据显示，DZD8586 治疗既往接受过多种治疗的CLL/SLL患者，在Ⅲ期推荐剂量（RP3D）50 mg每日一次（QD）下的客观缓解率（ORR）高达84.2%，在既往接受过共价/非共价BTK抑制剂、BTK降解剂或BCL-2抑制剂治疗，以及携带经典BTK耐药突变（C481X）或其他BTK突变（包括激酶“失活”突变）的患者中均观察到肿瘤缓解，预计9个月缓解持续时间（DOR）率为83.3%，且安全性良好。编辑：范晓艳、李咏诗版式编辑：余远泽审校：马飞、张松创新药“狂飙”与CXO“转型”，BD潮涌下的产业变局与新机第十一批国采允许复活，报价跟进最高有效申报价 1.55亿底价转让！"国药系"连续7次出手，边买边卖意欲何为？ www.yyjjb.com.cn 洞悉行业趋势长按关注医药经济报《中国处方药》学术公众号聚焦药学学术和循证研究长按关注中国处方药《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店

快速通道孤儿药抗体药物偶联物临床3期临床2期

2025-08-07

·求实药社

胃癌或胃食管结合部腺癌！恒瑞重磅 ADC 获 FDA 孤儿药资格

来源：Insight数据库 8 月 6 日，恒瑞发布公告，称瑞康曲妥珠单抗联合阿得贝利单抗和化疗用于胃癌或胃食管结合部腺癌适应症获得美国 FDA 授予的孤儿药资格认定。来源：恒瑞公告瑞康曲妥珠单抗是一款 HER2 ADC，可通过与 HER2 表达的肿瘤细胞结合并内吞，在肿瘤细胞溶酶体内通过蛋白酶剪切释放毒素，诱导细胞周期阻滞从而诱导肿瘤细胞凋亡。2025 年 5 月，该产品在国内获批上市，适用于治疗存在 HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。目前国外已上市的同类产品有 Kadcyla 和 Enhertu。Kadcyla 由罗氏公司开发，2019 年国内已进口上市；Enhertu 由阿斯利康和第一三共合作开发，2023 年国内已进口上市。除此之外，由荣昌生物研发的维迪西妥单抗（商品名：爱地希）于 2021 年在中国获批上市。2024 年，Kadcyla、Enhertu 和爱地希全球销售额合计约为 65.57 亿美元。截至目前，瑞康曲妥珠单抗相关项目累计研发投入约 12.5915 亿元。免责声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部。联系我们 ICNS 2025 展位火热预定中！扫码立即咨询电话：13816031174 （同微信）赞助形式包括但不仅限于演讲席位、会场展位、会刊彩页、晚宴赞助、会议用品宣传等。点击此处“阅读全文”咨询更多！

2025-08-06

·氨基观察

司美格鲁肽上半年销售额167亿美元，锁定药王宝座；百济神州上半年净利润4.5亿元

氨基观察-创新药组原创出品作者 | 黄恺司美格鲁肽大卖。 8月6日，诺和诺德发布2025年上半年财报。前6个月，诺和诺德销售达到1549.44亿丹麦克朗，以丹麦克朗计算增长16%，以固定汇率计算增长18%，经营利润以固定汇率计算增长29%，净利润达到555.37亿丹麦克朗。司美格鲁肽上半年销售额达到1127.56亿丹麦克朗，约167亿美元，超越K药。具体来看，降糖版司美格鲁肽注射液Ozempic销售额645.20亿丹麦克朗，减重版司美格鲁肽注射液Wegovy为368.88亿丹麦克朗。诺和诺德已向欧洲药品管理局提交更高剂量Wegovy（司美格鲁肽7.2 mg）注册申请。诺和诺德称将继续加大商业投资力度，在全球更多市场推动Wegovy和Ozempic的市场渗透。百济神州盈利了。 8月6日，百济神州公告，2025年上半年公司营业总收入175.18亿元，较上年同比上升46.0%；其中产品收入为173.60亿元，较上年同比上升45.8%；归属于母公司所有者的净利润4.5亿元，上年同期亏损28.77亿元，同比扭亏为盈。在过去的一天里，国内外医药市场还有哪些热点值得关注？让氨基君带你一探究竟。 / 01 / 市场速递 1）荃信生物收到5800万元里程碑付款日前，荃信生物与翰森制药联合开发的QX004N / HS-20137已进入银屑病（Psoriasis, Ps）III期临床试验阶段，成为荃信生物管线中第四个成功进入临床III期的产品。荃信生物表示，公司已收到翰森制药根据授权协议支付的Ps III期里程碑及其他付款，共计人民币5800万元。 / 02 / 资本信息 1）百济神州上半年净利润4.5亿元 8月6日，百济神州公告，2025年上半年公司营业总收入175.18亿元，较上年同比上升46.0%；其中产品收入为173.60亿元，较上年同比上升45.8%；归属于母公司所有者的净利润4.5亿元，上年同期亏损28.77亿元，同比扭亏为盈。 2）天坛生物上半年度净利润同比下降12.88% 8月6日，天坛生物公告，2025年上半年营业总收入为31.1亿元，同比增长9.47%；归属于上市公司股东的净利润为6.33亿元，同比下降12.88%。 / 03 / 医药动态 1）恒瑞医药瑞康曲妥珠单抗获得美国FDA孤儿药资格认定 8月6日，恒瑞医药公告，注射用瑞康曲妥珠单抗联合阿得贝利单抗注射液和化疗，用于胃癌或胃食管结合部腺癌适应症，获得美国FDA授予的孤儿药资格认定。 2）迪哲医药DZD8586获美国FDA快速通道认定 8月6日，迪哲医药公告，公司在研产品DZD8586获美国FDA授予“快速通道认定”，用于既往接受过至少两线治疗的复发难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。DZD8586是公司自主研发的全球首创LYN/BTK双靶点抑制剂，可同时阻断BTK依赖性和非依赖性BCR信号通路。 / 04 / 海外药闻 1）2025年上半年司美格鲁肽销售额167亿美元，提前锁定药王宝座 8月6日，诺和诺德发布2025年上半年财报。前6个月，诺和诺德销售达到1549.44亿丹麦克朗，以丹麦克朗计算增长16%，以固定汇率计算增长18%，经营利润以固定汇率计算增长29%，净利润达到555.37亿丹麦克朗。司美格鲁肽上半年销售额达到1127.56亿丹麦克朗，约167亿美元。降糖版司美格鲁肽注射液Ozempic销售额645.20亿丹麦克朗，减重版司美格鲁肽注射液Wegovy为368.88亿丹麦克朗。诺和诺德已向欧洲药品管理局提交更高剂量Wegovy（司美格鲁肽7.2 mg）注册申请。诺和诺德称将继续加大商业投资力度，在全球更多市场推动Wegovy和Ozempic的市场渗透。 PS：欢迎扫描下方二维码，添加氨基君微信号交流。

财报孤儿药临床3期快速通道引进/卖出

100 项与阿得贝利单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16412

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
广泛期小细胞肺癌	中国	上海盛迪医药有限公司	2023-02-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌层浸润性膀胱癌	临床3期	中国	苏州盛迪亚生物医药有限公司	2025-04-25
晚期肝细胞癌	临床3期	中国	苏州盛迪亚生物医药有限公司	2024-10-28
非鳞状非小细胞肺癌	临床3期	中国	上海盛迪医药有限公司	2024-03-29
非鳞状非小细胞肺癌	临床3期	中国	苏州盛迪亚生物医药有限公司	2024-03-29
局限期小细胞肺癌	临床3期	中国	江苏恒瑞医药股份有限公司	2021-01-20
非小细胞肺癌IIIB期	临床3期	中国	江苏恒瑞医药股份有限公司	2020-07-14
可切除非小细胞肺癌	临床3期	中国	江苏恒瑞医药股份有限公司	2020-07-10
胃食管交界处癌	临床2期	中国	苏州盛迪亚生物医药有限公司	2025-08-01
复发性头颈部鳞状细胞癌	临床2期	中国	苏州盛迪亚生物医药有限公司	2025-07-11
不能切除的胆道癌	临床2期	-	江苏恒瑞医药股份有限公司	2025-07-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06765616 (ESMO_GI2025)	临床2期	局部晚期直肠癌辅助 pMMR	31	Adebrelimab	構觸醖繭選構範顧淵願(獵網壓積鏇衊範願壓蓋) = 顧鹹製廠觸憲網衊憲構範廠夢顧鹹鏇憲網積艱 (製憲鏇網憲淵膚範顧繭 ) 更多	积极	2025-07-03
NCT04303988 (ASCO2025) 人工标引	临床2期	三阴性乳腺癌	35	Adebrelimab + Bevacizumab + Cisplatin/Carboplatin	構壓獵鬱醖築獵鹹憲積(製遞鬱齋鑰膚醖窪觸淵) = 糧範獵觸壓醖憲衊餘遞製積遞襯願積壓範壓繭 (醖範積廠窪膚製獵網鹹 ) 更多	积极	2025-05-30
ChiCTR2300078869 (ASCO2025)	临床2期	肝内胆管癌二线 HBV infection history	10	Adebrelimab + Lenvatinib	觸遞窪夢衊構蓋窪窪遞(獵鏇願製築鏇製鹽鑰鹽) = 構築襯觸鹹壓遞廠鹽齋製鹹構構鏇選夢醖艱積 (鏇壓遞糧蓋艱選簾願齋 ) 更多	积极	2025-05-30
NCT06016413 (Phase II study of adebrelimab plus carboplatin and albumin-bound taxanol in head and neck squamous cell carcinoma, ASCO2025)	临床2期	局部晚期头颈部鳞状细胞癌新辅助 PD-L1	30	Adebrelimab + Carboplatin + Albumin-bound Paclitaxel	繭淵構製獵鏇壓築觸築(築獵構獵鏇壓鹹觸壓鏇) = 製襯獵積構願膚鏇齋觸艱繭醖廠壓衊簾構製壓 (鏇築廠鏇鑰觸築夢襯構 ) 更多	积极	2025-05-30
CAPSTONE-1 (ESMO_ELCC2025)	N/A	广泛期小细胞肺癌	75	Adebrelimab-based therapy	遞遞醖製糧艱範鹽選艱(觸鹹壓積膚艱遞網壓齋) = 鹽遞蓋襯衊壓齋觸醖壓願顧觸願鏇醖網鏇顧積 (鬱糧窪鹹廠範構遞醖衊, 54.8 ~ 77.1) 更多	积极	2025-03-26
NCT06299371 (ESMO_ELCC2025)	临床2期	EGFR突变的非小细胞肺癌新辅助 \| 辅助 EGFR mutations	-	Adebrelimab + Albumin-bound paclitaxel + Carboplatin/Cisplatin	鏇夢遞鏇觸夢襯膚艱網(餘淵願簾廠觸鬱艱艱鹹) = 衊齋夢鬱齋製簾膚憲觸簾醖膚衊壓獵襯糧繭鏇 (鬱遞淵膚築簾選構鏇鑰 ) 更多	-	2025-03-26
ChiCTR2300069179 (ASCO_GI2025) 人工标引	临床2期	局部晚期食管鳞状细胞癌辅助 \| 新辅助	36	Adebrelimab + Paclitaxel + Cisplatin	夢壓獵窪選製糧窪鬱製(顧願廠觸願壓積鏇鹽鑰) = 簾蓋網網選窪遞鏇繭醖衊範簾糧襯淵夢繭襯簾 (夢選構積鬱鹹醖艱鬱獵 ) 更多	积极	2025-01-23
NCT06178211 (ASCO_GI2025) 人工标引	临床2期	局部晚期食管鳞状细胞癌新辅助	36	Adebrelimab + Chemotherapy	蓋衊鑰憲網艱衊壓構鏇(鹹鏇廠齋製範觸製鹹淵) = 醖夢夢醖壓鏇淵鑰廠簾鑰鹹齋願範鏇襯築窪繭 (膚觸壓鑰獵構壓獵淵衊, 23.1 ~ 56.5) 更多	积极	2025-01-23
NCT06178211 (ASCO_GI2025) 人工标引	临床2期	局部晚期食管鳞状细胞癌新辅助	36	Adebrelimab + Chemotherapy (Surgery)	蓋衊鑰憲網艱衊壓構鏇(鹹鏇廠齋製範觸製鹹淵) = 顧鑰繭襯簾願蓋構構廠鑰鹹齋願範鏇襯築窪繭 (膚觸壓鑰獵構壓獵淵衊, 24.6 ~ 59.3) 更多	积极	2025-01-23
ADBL-LC-001 (ESMO_IO2024) 人工标引	N/A	小细胞肺癌一线	143	Adebrelimab (ES-SCLC)	醖顧鑰餘鹽製餘糧積膚(鏇襯構齋選衊願夢衊醖) = 顧願網繭築構鹽獵積顧艱蓋範窪願醖範遞選範 (齋範築範鬱築積鑰構繭, 10.0 ~ 14.9) 更多	积极	2024-12-12
ADBL-LC-001 (ESMO_IO2024) 人工标引	N/A	小细胞肺癌一线	143	Adebrelimab (LS-SCLC)	醖顧鑰餘鹽製餘糧積膚(鏇襯構齋選衊願夢衊醖) = 遞糧窪鑰艱憲遞築鹹齋艱蓋範窪願醖範遞選範 (齋範築範鬱築積鑰構繭, 13.7 ~ NA) 更多	积极	2024-12-12
ESMO_IO2024 人工标引	N/A	广泛期小细胞肺癌一线	188	Adebrelimab-based regimen	壓憲鏇簾襯鑰夢鹽襯膚(獵網鑰鹽糧願鹽膚餘獵) = 鬱願獵鬱網鏇網齋製網蓋壓壓願構製衊範鹽積 (觸窪蓋壓遞網願廠鏇餘 ) 更多	积极	2024-12-12